ANNEX 
CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND 
EFFECTIVE USE OF THE MEDICINAL PRODUCT TO BE IMPLEMENTED 
BY THE MEMBER STATES 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CONDITIONS  OR  RESTRICTIONS  WITH  REGARD  TO  THE  SAFE  AND 
EFFECTIVE  USE  OF  MEDICINAL  PRODUCT  TO  BE  IMPLEMENTED  BY 
THE MEMBER STATES 
The  Member  States  should  ensure  that  all  conditions  or  restrictions  with  regard  to  the  safe  and 
effective use of the medicinal product described below are implemented: 
The Marketing authorisation Holder (MAH) shall ensure that prior to launch of the prefilled syringe 
form  of  Stelara,  all  healthcare  professionals  who  are  expected  to  prescribe/use  Stelara  are  provided 
with educational materials containing the following: 
Healthcare Professional educational pack 
•  Patient information pack 
The key messages and components included in the Healthcare Professional educational pack are 
defined as follows: 
•  Summary of Product Characteristics 
•  Local Guidance for tuberculosis screening; 
•  Risk of serious infections, including salmonella, tuberculosis, and other mycobacterial 
infections; 
•  Risk of hypersensitivity reactions, including latex allergy warning and contraindication; 
•  Risk of malignancies. 
The key messages in the patient information pack are defined as follows: 
•  Patient Information Leaflet 
•  Risk of reactivation of latent tuberculosis and information about the screening for tuberculosis 
according to the local guidance; 
•  Risk of serious infections, including salmonella, tuberculosis, and other mycobacterial 
infections; 
•  Risk of hypersensitivity reactions, including latex allergy warning and contraindication;  
•  Potential risk of malignancies; 
•  Appropriate techniques for self administration of Stelara, including use of the prefilled 
syringes. 
Page 2 of 2 
 
 
 
 
 
 
 
